RTTNews | Nov 3, 2021 11:27AM EDT

11:27 Wednesday, November 3, 2021 (RTTNews.com) - Shares of nano-cap company Petros Pharmaceuticals, Inc. (PTPI) more than doubled on Wednesday morning after the pharma company announced a 476% growth year-over-year of STENDRA tablet sales as part of an exclusive digital health marketing agreement with Hims & Hers Health, Inc.

The companies also announce the availability of additional dosages of STENDRA through the Hims & Hers platform, further expanding the partnership.

PTPI is currently trading at $3.5199, up $1.7699 or 101.1371%, on the Nasdaq, on a heavy volume of 134 million compared to average volume of 94 thousand shares.

Stendra (avanafil), originally launched by Auxilium Pharmaceuticals prior to that company's sale to Endo Pharmaceuticals, is an oral phosphodiesterase 5 (PDE5) inhibitor for the treatment of erectile dysfunction.

Read the original article on RTTNews ( https://www.rttnews.com/3238991/petros-pharmaceuticals-stock-doubles-on-stendra-sales-growth.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved